Regular articleProlactin and prolactin secretagogues reverse immunosuppression in mice treated with cysteamine, glucocorticoids, or cyclosporin-A
References (44)
- et al.
Characterization of immunoreactive IGF-1 from leukocytes and its regulation by growth hormone
Endocrinology
(1991) - et al.
Prolactin binding sites in human erythrocytes and lymphocytes
Life Sci
(1987) - et al.
Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice
Science
(1988) - et al.
Prolactin, growth hormone, and immune homeostasis
- et al.
Morphine pellet induced immunosuppression in mice: Temporal relationships
J. Pharmacol. Exp. Ther
(1988) - et al.
Cysteamine produces dose related bidirectional immunomodulatory effects in mice
J. Pharmacol. Exp. Ther
(1989) - et al.
Suppressive effects of morphine pellet implants on in vivo parameters of immune function
J. Pharmacol. Exp. Ther
(1990) - et al.
Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment
Endocrinology
(1991) - et al.
Rapid elevation of rat serum prolactin concentration by cyclosporine, a novel immunosuppressive drug
Biochem. Biophys. Res. Comm
(1984) - et al.
Effects of low-dose dopamine infusion on basal and stimulated TSH and prolactin concentrations in man
Clin. Endocrinol
(1985)
Corticosteroid-mediated immunoregulation in man
Immunol. Rev
Prolactin regulation of membrane fluidity and prostaglandin formation
A human B-lymphoblastoid cell line produces prolactin
Endocrinology
The pituitary gland is required for protection against lethal effects of Salmonella typhimurium
In vivo administration of recombinant growth hormone or gamma interferon activates macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates
Infect. Immun
Decrease of morphine-induced prolactin release by a procedure causing prolonged stress
J. Endocrinol
Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor
J. Clin. Invest
Blunted prolactin response to thyrotropin-releasing hormone stimulation in cystinotic children receiving cysteamine
J. Clin Endocrinol. Metab
Regulation of prolactin secretion in the human B-lymphoblastoid cell line IM-9-P3 by dexamethasone but not other regulators of pituitary prolactin secretion
Endocrinology
Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH
Endocrinology
Glucocorticoid-induced inhibition of T cell growth factor production
J. Immunol
Inhibition of lymphocyte proliferation by antibodies to prolactin
FASEB J
Cited by (43)
Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial
2019, Neurobiology of DiseaseCitation Excerpt :Aside from their prominent anti-oxidant role, cystamine and cysteamine have also been demonstrated to be hepatoprotective against acetaminophen poisoning, by enhancing levels of the antioxidant glutathione (Peterson and Brown, 1992; Prescott et al., 1976; Prescott et al., 1974). More recently, these molecules have been recognized as antiviral agents effective against influenza A and hepatitis A (Biziagos et al., 1987; Hamzehei and Ledinko, 1980), and more remarkably against the human immunodeficiency virus (HIV)-1 ((Ho et al., 1996, Ho et al., 1995; Bergamini et al., 1994; also see Toohey, 2009 for review) (Fig. 1) (Ferrari et al., 2017; Zhang et al., 2015; Besouw et al., 2013; Wan et al., 2011; Min-Oo et al., 2010; Pillai et al., 2008; Min-Oo et al., 2007; Tremblay et al., 2006; Jeon et al., 2004; Kleta and Gahl, 2004; Lesort et al., 2003; Dedeoglu et al., 2002; Karpuj et al., 2002; Bogdanov et al., 2001; Suwannaroj et al., 2001; Gahl et al., 2000; Jeitner and Renton, 1996; Markello et al., 1993; Bernton et al., 1992; Benke et al., 1990; Kaiser-Kupfer et al., 1990; Bryant et al., 1989; Haroutunian et al., 1987; Kaiser-Kupfer et al., 1987; Shults et al., 1986; Szabo and Reichlin, 1981; Girardin et al., 1979; Cohen et al., 1976; Hassan et al., 1976). Indeed, cysteamine, in various different preparations, holds 7 rare drug designations, including treating cystic fibrosis (De Stefano and Maiuri, 2015) and pancreatic cancer (Food and Drug Administration, 2018; Fujisawa et al., 2012) as well as being approved by the Food and Drug administration (FDA) and the European Medicines Agency (EMA) for cystinosis since 1994.
Chronobiology in the endocrine system
2007, Advanced Drug Delivery ReviewsAgeing and the endocrine circadian system
2004, NeuroImmune BiologyCitation Excerpt :Reducing endogenous levels of prolactin with bromocriptine inhibited immune functions only when the drug was administered during this daily interval of immunoregulatory sensitivity to the hormone [145]. This observation is similar to that of Bernton et al [150] who found that the effect of the prolactin inhibitor Cysteamine (a dopamine beta-hydroxylase inhibitor) on splenocyte mitogenic response was circadian time dependent. Prolactin effects on immune activity and immunologic disorders were reported in human subjects including lupus erythematosus and the post-partum exacerbation of rheumatoid arthritis [146,151–153,156].
Dopamine, a neurotransmitter, influences the immune system
2000, Journal of Neuroimmunology
- 1
Currently at Lilly Research Institute, Eli Lilly and Co., Indianapolis, IN.
- 2
Currently at EntreMed, Inc., Rockville, MD.